DOCSLIB.ORG

Buyers' Guide

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Buyers' Guide Buyers’ Guide S119 Buyers’ Guide Suppliers’ Contact Details Amersham Biosciences UK Limited The Menarini Group Amersham Place www.menarini.com Little Chalfont Buckinghamshire HP7 9NA Moravek Biochemicals UK 577 Mercury Lane www5.amershambiosciences.com Brea Ca 92821 Avanti Polar Lipids Inc USA 700 Industrial Park Drive www.moravek.com Alabaster AL 35007 Roche Pharmaceuticals USA F. Hoffmann-La Roche Ltd www.avantilipids.com Pharmaceuticals Division Grenzacherstrasse 124 Bachem Bioscience Inc. CH-4070 Basel 3700 Horizon Drive Switzerland King of Prussia Telephone þ 41-61-688 1111 PA 19406 Unites States Telefax þ 41-61-691 9391 www.bachem.org www.roche.com Boehringer Ingelheim Ltd Ellesfield Avenue SIGMA Chemicals/Sigma-Aldrich Bracknell P.O. Box 14508 Berks RG12 8YS St. Louis, MO 63178-9916 UK USA www.boehringer-ingelheim.co.uk www.sigma-aldrich.com Calbiochem Tocris Cookson Ltd. EMD Biosciences, Inc. Northpoint, Fourth Way 10394 Pacific Center Court Avonmouth San Diego Bristol CA 92121 BS11 8TA USA UK www.emdbiosciences.com www.tocris.com S120 Buyers’ Guide Compound Supplier Buyers’ Guide a-methyl-5-HT a-Methyl-5-hydroxytryptamine Tocris ab-meATP ab-methylene-adenosine 5’-triphosphate Sigma-Aldrich bg-meATP bg-methylene-adenosine 5’-triphosphate Sigma-Aldrich (-)-(S)-BAYK8664 (-)-(S)-methyl-1,4-dihydro-2,6-dimethyl-3-nitro-4-(2-trifluromethylphenyl)-pyridine-5-carboxylate Sigma-Aldrich, Tocris (+)7-OH-DPAT (+)-7-hydroxy-2-aminopropylaminotetralin Sigma-Aldrich a-dendrotoxin Sigma-Aldrich (RS)PPG (R,S)-4-phosphonophenylglycine Tocris (S)-3,4-DCPG (S)-3,4-dicarboxylphenylglycine Tocris [Ala1,3,11,15]ET-1 Sigma-Aldrich 12-(S)-HPETE 12-(S)-hydroperoxyeicosatetraenoic acid Sigma-Aldrich 1400W N-(3-(aminomethyl)benzyl)acetamidine Sigma-Aldrich, Tocris 15-(S)-HPETE 15-(S)-hydroperoxyeicosatetraenoic acid Sigma-Aldrich 15deoxy-PGJ2 Sigma-Aldrich 1S,3R-ACPD 1-aminocyclopentane-1S,3R-dicarboxylate Sigma-Aldrich, Tocris 2-APB 2-amino ethoxyphenylborate Tocris 2Cl-IB-MECA 2-chloro-N6-(3-iodobenzyl)adenosine-5’-N-methyluronamide Sigma-Aldrich, Tocris 2-MeSADP 2-methylthio-adenosine-5’-diphosphate Sigma-Aldrich 2-MeSATP 2-methylthio-adenosine-5’-triphosphate Sigma-Aldrich 2R,4R-APDC aminopyrrolidine-2R,4R-dicarboxylate also known as LY314593 Tocris 3-APMPA 3-amino-propyl-(P-methyl)-phosphinic acid, also known as CGP35024 3HPG 3-hydroxyphenylglycine Sigma-Aldrich, Tocris 4a-PDD 4a-phorbol 12,13-didecanoate Sigma-Aldrich 4-AP 4-aminopyridine Sigma-Aldrich 4CPG 4-carboxyphenylglycine Sigma-Aldrich, Tocris 4-DAMP 4-diphenylacetoxy-N-methylpiperidine methiodide Sigma-Aldrich, Tocris 4P-PDOT 4-phenyl-2-propionamidotetraline Tocris 5-(S)-HETE 5-(S)-hydroeicosatetraenoic acid Sigma-Aldrich 5-CT 5-carboxamidotryptamine Sigma-Aldrich, Tocris 5-fluoro-20-deoxyuridine Sigma-Aldrich 5-fluorouridine Sigma-Aldrich 5MCA-NAT 5-methoxy-carbonylamino-N-acetyltryptamine, also known as GR 135531 Sigma-Aldrich, Tocris 7NI 7-nitroindazole Sigma-Aldrich, Tocris 8-OH-DPAT 8-hydroxy-2-(di-n-propylamino)tetralin Sigma-Aldrich, Tocris 9-AC Anthracene-9-carboxylic acid Sigma-Aldrich, Tocris A61603 N-(5-[4,5-dihydro-1H-imidazol-2-y]-2-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)methanesulphonamide hydrobromide Tocris AB-MECA N6-(4-aminobenzyl)-adenosine-5’-N-methyluronamide Sigma-Aldrich ABT-418 (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole Sigma-Aldrich AC187 acetyl-[Asn30,Tyr32]salmon calcitonin Sigma-Aldrich adenophostin A Sigma-Aldrich AFDX384 (7)-5,11-dihydro-11-([{2-(2-N,N-[dipropylamino]methyl)piperidin-1-yl}ethylamino]carbonyl)- Tocris 6H-pyrido[2,3-b](1,4)benzodiazepine-6-one AG-3-5 1-[2-hydroxyphenyl]-4[3-nitrophenyl]-1,2,3,6-tetrahydropyrimidine-2-one Sigma-Aldrich, Tocris AGN192093 (Z)-7-([1a,5a,6a,7b]-7-[{1E,3S}-3-hydroxy-1-octenyl]-3-oxo-2,4-dioxobicyclo[3.2.1]oct-6-yl)-5-heptenol Sigma-Aldrich AH13205 trans-2-(4-[1-hydroxyhexyl]phenyl)-5-oxocyclopentaneheptanoate Sigma-Aldrich AH23848 (1a[z],2b,5a)-(7)-7-(5-[{(1,10-biphenyl)-4-yl}methoxy]-2-[4-morpholinyl]-3-oxocyclopentyl)-4-heptenoate Sigma-Aldrich AIDA 1-aminoindan-1,5(RS)-dicarboxylic acid, also known as UPF523 Sigma-Aldrich, Tocris AM630 6-iodopravadoline Sigma-Aldrich, Tocris AMPA (RS)-a-amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid Sigma-Aldrich, Tocris Anandamide Tocris Antalarmin N-butyl-N-ethyl-(2,5,6-trimethyl)-7-[2,4,6-trimethylphenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl-amine Sigma-Aldrich Compound Supplier Apamin Bachem, Sigma-Aldrich ARC239 2-[2-(4-(2-Methoxyphenyl)piperazin-1-yl)ethyl]-4,4-dimethyl-1,3-(2H,4H)-isoquinolindione dihydrochloride Tocris Astemizole Sigma-Aldrich Astressin cyc30–33[d-Phe12,Nle21,38,Glu30,Lys33]CRF-(12-41) Sigma-Aldrich, Tocris ATPO (RS)-2-amino-3-(3-[5-tert-butyl-3-(phosphonomethoxy)-4-isoxazolyl]propionic acid Sigma-Aldrich ATPgS Adenosine 5’-(3-thio)triphosphate Roche, Sigma-Aldrich ATRA all-trans-retinoic acid AZT 30-azido-30-deoxythymidine Sigma-Aldrich BADGE bisphenol A diglycidyl ether Sigma-Aldrich, Tocris BAYu9773 6(R)-(40-carboxyphenyl-thio)-5(S)-hydroxy-7(E),11(Z),14(Z)-eicosatetraenoic acid Sigma-Aldrich Bezafibrate 2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]-2-methylpropanoic acid Sigma-Aldrich BHT920 6-allyl-2-amino-5,6,7,8-tetrahydro-4H-thiazolo-[4,5-d]-azepine Sigma-Aldrich BIBP3226 R-N2-(diphenylacetyl)-N-(4-hydroxyphenyl)methyl-argininamide Sigma-Aldrich BIM23056 dPhe-Phe-Tyr-dTrp-Lys-Val-Phe-dNal-NH2 Tocris BIM23127 D-Nal-cyc[Cys-Tyr-D-Trp-Orn-Val-Cys]-Nal-NH2 Bachem, Tocris BMY45778 3-(4-[4,5-diphenyl-2-oxazolyl]-5-oxazolyl)phenoxyacetic acid Tocris BMY7378 8-(2-[4-{2-methoxyphenyl}-1-piperazinyl]ethyl)-8-azaspiro[4,5]decane-7,9-dione dihydrochloride Sigma-Aldrich, Tocris bosentan Bachem BQ123 cyc(dTrp-dAsp-Pro-dVal-Leu) Sigma-Aldrich BQ3020 N-acetyl-Leu-Met-Asp-Lys-Glu-Ala-Val-Tyr-Phe-Ala-His-Leu-Asp-Ile-Ile-Trp Sigma-Aldrich BQ788 N-cis-2,6-dimethylpiperidinocarbonyl-L-g-methylleucyl-D-1-methoxycarboyl-D-norleucine Sigma-Aldrich BRL15572 3-[4-(3-chlorophenyl) piperazin-1-yl]-1,1,-diphenyl-2-propanol Sigma-Aldrich, Tocris BRL37344 sodium 4-(2-[2-hydroxy-3-chlorophenyl}ethylamino]propyl)phenoxyacetate Sigma-Aldrich, Tocris BRL44408 2-(2H-[1-methyl-1,3-dihydroisoindole]methyl)-4,5-dihydroimidazole Sigma-Aldrich, Tocris BRL54443 3-(1-methylpiperidin-4-yl)1H-indol-5-ol Sigma-Aldrich, Tocris BW245C 5-(6-carboxyhexyl)-1-(3-cyclohexyl-3-hydroxypropyl)hydantoin Sigma-Aldrich BW723C86 1-[5(2-thienylmethoxy)-1H-3-indolyl]propan-2-amine hydrochloride Sigma-Aldrich, Tocris BWA868C 3-benzyl-5-(6-carboxyhexyl)-1-(2-cyclohexyl-2-hydroxyethylamino)hydantoin Sigma-Aldrich C7 galanin-1–13-spantide Sigma-Aldrich caffeine 1,3,7-Trimethylxanthine Sigma-Aldrich calciseptine Calbiochem Calphostin C Sigma-Aldrich CCPA 2-chloro-N6-cyclopentyladenosine Sigma-Aldrich, Tocris CGP12177A (-)-4-(3-tert-butylamino-2-hydroxypropoxy)-benzimidazol-2-one Sigma-Aldrich, Tocris CGP20712A 2-hydroxy-5-(2-[{2-hydroxy-3-(4-[1-methyl-4-trifluoromethyl-2-imidazolyl]phenoxy)propyl}amino]ethoxy)benzamide Sigma-Aldrich, Tocris CGP35024 3-amino-propyl-(P-methyl)-phosphinic acid, also known as 3-APMPA CGP35348 p-(3-aminopropyl)-P-diethoxymethylphosphinic acid Tocris CGP37849 (RS)-(E)-2-amino-4-methylphosphono-3-pentanoic acid Sigma-Aldrich, Tocris CGP42112A nicotinic acid-Tyr-(N-benzoylcarbonyl-Arg)-Lys-His-Pro-Ile-OH CGP54626 [S-(R,R)]-[3-[[1-(3,4-dichlorophenyl)ethyl]amino]-2-hydroxypropyl](cyclohexylmethyl)phosphinic acid Tocris CGP55845 3-[-1-(S)-(3,4-dichlorphenyl)-ethyl]amino-2(S)-hydroxypropyl-(P-benzyl)-phosphinic acid Tocris CGP61594 (7)-trans-4-[2-(4-azidophenyl)acetylamino]-5,7-dichloro-1,2,3,4-tetrahydroquinoline-2-carboxylic acid Sigma-Aldrich CGP62349 [3-[1-R-[[3-(methoxyphenylmethyl)hydroxyphosphinyl]-2(5)-hydroxypropyl]amino]ethyl]-benzoic acid Sigma-Aldrich CGP64213 [3-[-(R)-[[3-5N-[1-[2-[[3-iodo-4-hydroxyphenyl]ethyl]carboxamido]pentyl]hydroxyphosphinyl]-2(S)- Sigma-Aldrich hydroxy-propyl]amino]ethyl-benzoic acid Buyers’ Guide S121 CGP71683A trans-naphthalene-1-sulphonic acid(4-[4-amino-quinazolin-2-ylamino]-methyl)-cyclohexylmethyl-amide hydrochloride Sigma-Aldrich CGS15943 5-amino-9-chloro-2-(2-furyl)1,2,4-triazolo[1,5-c]quinazoline Sigma-Aldrich, Tocris CGS19755 4-phosphonomethyl-2-piperidinecarboxylic acid Tocris CGS21680 2-(4-[2-carboxyethyl]-phenethylamino)adenosine-5’-N-ethyluronamide Sigma-Aldrich, Tocris CGS25019C 4-(5-[4-{aminoiminomethyl}phenoxy]pentoxy)-3-methoxy-N,N-bis(1-methylethyl)benzamide-(Z)-2-butenedioate Sigma-Aldrich charybdotoxin Bachem, Calbiochem chelerythrine Sigma-Aldrich, Tocris S122 Compound Supplier CHPG (RS)-2-chloro-5-hydroxyphenylglycine Sigma-Aldrich, Tocris Buyers’ Guide CI966 (1-[2-{bis-4(trifluromethyl)phenyl}methoxy]ethyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylic acid Sigma-Aldrich, Tocris CI977 (5R)-(5a,7a,8b)-(–)-N-methyl-N-(7-[1-pyrrolidinyl]-1-oxaspiro[4,5]dec-8-yl)-4-benzofuranacetamide monohydrochloride Sigma-Aldrich ciglitizone (7)-5-[4-(1-Methylcyclohexylmethoxy)benzyl]thiazolidine-2,4-dione Sigma-Aldrich, Tocris CL316243 disodium (R,R)-5-(2-[{2-(3-chlorophenyl)-2-hydroxyethyl}-amino]propyl)-1,3-benzodioxole-2,2,dicarboxylate Tocris clofibrate Sigma-Aldrich (may not be available in US due to patent issues), Tocris CNQX 6-cyano-7-nitroquinoxaline-2,3-dione Sigma-Aldrich, Tocris CP101606 (1S,2S)-1-4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol Sigma-Aldrich CP195543 (+)-2-(3-benzyl-4-hydroxychroman-7-yl)-4-trifluoromethylbenzoic acid Sigma-Aldrich CP55940 (-)-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-4-(3-hydroxypropyl)cyclohexan-1-ol Sigma-Aldrich, Tocris CPA N6-cyclopentyladenosine Tocris CPCCOEt cyclopropan[b]chromen-1a-carboxylate
Load more

Recommended publications
  • The G Protein-Coupled Glutamate Receptors As Novel Molecular Targets in Schizophrenia Treatment— a Narrative Review
    Journal of Clinical Medicine Review The G Protein-Coupled Glutamate Receptors as Novel Molecular Targets in Schizophrenia Treatment— A Narrative Review Waldemar Kryszkowski 1 and Tomasz Boczek 2,* 1 General Psychiatric Ward, Babinski Memorial Hospital in Lodz, 91229 Lodz, Poland; [email protected] 2 Department of Molecular Neurochemistry, Medical University of Lodz, 92215 Lodz, Poland * Correspondence: [email protected] Abstract: Schizophrenia is a severe neuropsychiatric disease with an unknown etiology. The research into the neurobiology of this disease led to several models aimed at explaining the link between perturbations in brain function and the manifestation of psychotic symptoms. The glutamatergic hypothesis postulates that disrupted glutamate neurotransmission may mediate cognitive and psychosocial impairments by affecting the connections between the cortex and the thalamus. In this regard, the greatest attention has been given to ionotropic NMDA receptor hypofunction. However, converging data indicates metabotropic glutamate receptors as crucial for cognitive and psychomotor function. The distribution of these receptors in the brain regions related to schizophrenia and their regulatory role in glutamate release make them promising molecular targets for novel antipsychotics. This article reviews the progress in the research on the role of metabotropic glutamate receptors in schizophrenia etiopathology. Citation: Kryszkowski, W.; Boczek, T. The G Protein-Coupled Glutamate Keywords: schizophrenia; metabotropic glutamate receptors; positive allosteric modulators; negative Receptors as Novel Molecular Targets allosteric modulators; drug development; animal models of schizophrenia; clinical trials in Schizophrenia Treatment—A Narrative Review. J. Clin. Med. 2021, 10, 1475. https://doi.org/10.3390/ jcm10071475 1. Introduction Academic Editors: Andreas Reif, Schizophrenia is a common debilitating disease affecting about 0.3–1% of the human Blazej Misiak and Jerzy Samochowiec population worldwide [1].
    [Show full text]
  • Activation of Group I Metabotropic Glutamate Receptors Reduces Neuronal Apoptosis but Increases Necrotic Cell Death in Vitro
    Cell Death and Differentiation (2000) 7, 470 ± 476 ã 2000 Macmillan Publishers Ltd All rights reserved 1350-9047/00 $15.00 www.nature.com/cdd Activation of group I metabotropic glutamate receptors reduces neuronal apoptosis but increases necrotic cell death in vitro JW Allen1,2, SM Knoblach1,3 and AI Faden*,1,3,4 hydroxyphenylglycine; DHPG, dihydroxyphenylglycine; MK801, dizocilpine; LDH, lactate dehydrogenase; MCPG, -methyl-4- 1 Institute for Cognitive and Computational Sciences, Georgetown University carboxyphenylglycine; mGluR, metabotropic glutamate receptors; Medical Center, Washington, DC 20007, USA OGD, oxygen-glucose deprivation; TBI, traumatic brain injury 2 Interdisciplinary Program in Neuroscience, Georgetown University Medical Center, Washington, DC 20007, USA 3 Department of Neuroscience, Georgetown University Medical Center, Washington, DC 20007, USA Introduction 4 Department of Pharmacology, Georgetown University Medical Center, Washington, DC 20007, USA Activation of both ionotropic and metabotropic glutamate * Corresponding author: AI Faden, EP-04 Research Building, 3970 Reservoir receptors has been implicated in the pathophysiology of Road, N.W. Washington, DC 20007, USA. Tel: (202) 687 0492; Fax: (202) 687 stroke and CNS trauma. It has been well established that 0617; E-mail: [email protected] blockade of ionotropic glutamate receptors provides neuro- protection in vitro and in vivo.1±5 Recent studies have suggested that metabotropic glutamate receptors (mGluR) Received 23.7.99; revised 19.1.00; accepted 7.2.00 are also activated following traumatic brain injury (TBI)6±9 or Edited by FD Miller cerebral ischemia,10 or in vitro neuronal trauma7,9 or ischemia,11,12 leading to neuroprotection or exacerbation depending upon the mGluR subtype activated.
    [Show full text]
  • Amino Acids by G.C.BARRETT
    1 Amino Acids By G.C.BARRETT 1 Introduction The chemistry and biochemistry of the amino acids as represented in the 1992 literature, is covered in this Chapter. The usual policy for this Specialist Periodical Report has been continued, with almost exclusive attention in this Chapter, to the literature covering the natural occurrence, chemistry, and analysis methodology for the amino acids. Routine literature covering the natural distribution of well-known amino acids is excluded. The discussion offered is brief for most of the papers cited, so that adequate commentary can be offered for papers describing significant advances in synthetic methodology and mechanistically-interesting chemistry. Patent literature is almost wholly excluded but this is easily reached through Section 34 of Chemical Abstracts. It is worth noting that the relative number of patents carried in Section 34 of Chemical Abstracts is increasing (e.g. Section 34 of Chem-Abs., 1992, Vol. 116, Issue No. 11 contains 45 patent abstracts, 77 abstracts of papers and reviews), reflecting the perception that amino acids and peptides are capable of returning rich commercial rewards due to their important physiological roles and consequent pharmaceutical status. However, there is no slowing of the flow of journal papers and secondary literature, as far as the amino acids are concerned. The coverage in this Chapter is arranged into sections as used in all previous Volumes of this Specialist Periodical Report, and major Journals and Chemical Abstracts (to Volume 118, issue 11) have
    [Show full text]
  • Development of Allosteric Modulators of Gpcrs for Treatment of CNS Disorders Hilary Highfield Nickols A, P
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Neurobiology of Disease 61 (2014) 55–71 Contents lists available at ScienceDirect Neurobiology of Disease journal homepage: www.elsevier.com/locate/ynbdi Review Development of allosteric modulators of GPCRs for treatment of CNS disorders Hilary Highfield Nickols a, P. Jeffrey Conn b,⁎ a Division of Neuropathology, Department of Pathology, Microbiology and Immunology, Vanderbilt University, USA b Department of Pharmacology, Vanderbilt University, Nashville, TN 37232, USA article info abstract Article history: The discovery of allosteric modulators of G protein-coupled receptors (GPCRs) provides a promising new strategy Received 25 July 2013 with potential for developing novel treatments for a variety of central nervous system (CNS) disorders. Tradition- Revised 13 September 2013 al drug discovery efforts targeting GPCRs have focused on developing ligands for orthosteric sites which bind en- Accepted 17 September 2013 dogenous ligands. Allosteric modulators target a site separate from the orthosteric site to modulate receptor Available online 27 September 2013 function. These allosteric agents can either potentiate (positive allosteric modulator, PAM) or inhibit (negative allosteric modulator, NAM) the receptor response and often provide much greater subtype selectivity than Keywords: Allosteric modulator orthosteric ligands for the same receptors. Experimental evidence has revealed more nuanced pharmacological CNS modes of action of allosteric modulators, with some PAMs showing allosteric agonism in combination with pos- Drug discovery itive allosteric modulation in response to endogenous ligand (ago-potentiators) as well as “bitopic” ligands that GPCR interact with both the allosteric and orthosteric sites. Drugs targeting the allosteric site allow for increased drug Metabotropic glutamate receptor selectivity and potentially decreased adverse side effects.
    [Show full text]
  • Evidence for Metabotropic Glutamate Receptor Activation in the Induction of Depolarization-Induced Suppression of Inhibition in Hippocampal CA1
    The Journal of Neuroscience, July 1, 1998, 18(13):4870–4882 Evidence for Metabotropic Glutamate Receptor Activation in the Induction of Depolarization-Induced Suppression of Inhibition in Hippocampal CA1 Wade Morishita, Sergei A. Kirov, and Bradley E. Alger Department of Physiology, University of Maryland School of Medicine, Baltimore, Maryland 21201 Depolarization-induced suppression of inhibition (DSI) is a tran- (1S,3R)-ACPD-induced IPSC suppression and markedly re- sient reduction of GABAA receptor-mediated IPSCs that is duced DSI, whereas group III antagonists had no effect on DSI. mediated by a retrograde signal from principal cells to interneu- Many other similarities between DSI and the (1S,3R)-ACPD- rons. Using whole-cell recordings, we tested the hypothesis induced suppression of IPSCs also were found. Our data sug- that mGluRs are involved in the DSI process in hippocampal gest that a glutamate-like substance released from pyramidal CA1, as has been proposed for cerebellar DSI. Group II mGluR cells could mediate CA1 DSI by reducing GABA release from agonists failed to affect either evoked monosynaptic IPSCs or interneurons via the activation of group I mGluRs. DSI, and forskolin, which blocks cerebellar DSI, did not affect CA1 DSI. Group I and group III mGluR agonists reduced IPSCs, Key words: IPSP; GABA; retrograde signal; voltage clamp; but only group I agonists occluded DSI. (S)-MCPG blocked mGluR; synaptic inhibition Depolarization-induced suppression of inhibition (DSI) is a phe- decrease cAMP production (Conn et al., 1994), which can reduce nomenon seen in both hippocampal CA1 pyramidal cells (Pitler GABA release (Capogna et al., 1995).
    [Show full text]
  • G Protein-Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors Stephen PH Alexander1, Anthony P Davenport2, Eamonn Kelly3, Neil Marrion3, John A Peters4, Helen E Benson5, Elena Faccenda5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, 2Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK, 3School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK, 4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK, 5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/ 10.1111/bph.13348/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading.
    [Show full text]
  • Microglial Glutathione and Glutamate: Regulation Mechanisms
    Microglial glutathione and glutamate: Regulation mechanisms Victoria Anne Honey Fry UCL Institute of Neurology A thesis submitted for the degree of Doctor of Philosophy (Ph.D.) 1 I, Victoria Fry, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. 2 Abstract Microglia, the immune cells of the central nervous system (CNS), are important in the protection of the CNS, but may be implicated in the pathogenesis of neuroinflammatory disease. Upon activation, microglia produce reactive oxygen and nitrogen species; intracellular antioxidants are therefore likely to be important in their self-defence. Here, it was confirmed that cultured microglia contain high levels of glutathione, the predominant intracellular antioxidant in mammalian cells. The activation of microglia with lipopolysaccharide (LPS) or LPS + interferon- was shown to affect their glutathione levels. GSH levels in primary microglia and those of the BV-2 cell line increased upon activation, whilst levels in N9 microglial cells decreased. - Microglial glutathione synthesis is dependent upon cystine uptake via the xc transporter, which exchanges cystine and glutamate. Glutamate is an excitatory neurotransmitter whose extracellular concentration is tightly regulated by excitatory amino acid transporters, as high levels cause toxicity to neurones and other CNS cell types through overstimulation of - glutamate receptors or by causing reversal of xc transporters. Following exposure to LPS, increased extracellular glutamate and increased levels of messenger ribonucleic acid - (mRNA) for xCT, the specific subunit of xc , were observed in BV-2 and primary microglial cells, suggesting upregulated GSH synthesis.
    [Show full text]
  • 1 Activation of the Same Mglur5 Receptors in the Amygdala Causes Divergent Effects 2 on Specific Versus Indiscriminate Fear 3
    1 Activation of the same mGluR5 receptors in the amygdala causes divergent effects 2 on specific versus indiscriminate fear 3 4 Mohammed Mostafizur Rahman1,2,#, Sonal Kedia1,#, Giselle Fernandes1#, Sumantra 5 Chattarji1,2,3* 6 7 1National Centre for Biological Sciences, Tata Institute of Fundamental Research, 8 Bangalore 560065, India 9 10 2Centre for Brain Development and Repair, Institute for Stem Cell Biology and 11 Regenerative Medicine, Bangalore 560065, India 12 13 3Centre for Integrative Physiology, Deanery of Biomedical Sciences, University of 14 Edinburgh, Hugh Robson Building, George Square, Edinburgh EH89XD, UK 15 16 17 * Corresponding Author: Prof. Sumantra Chattarji 18 Centre for Brain Development and Repair, Institute for 19 Stem Cell Biology and Regenerative Medicine and 20 National Centre for Biological Sciences 21 Bangalore 560065, INDIA 22 E-Mail: [email protected] 23 # Equal contribution 24 1 25 Abstract 26 27 Although mGluR5-antagonists prevent fear and anxiety, little is known about how the 28 same receptor in the amygdala gives rise to both. Combining in vitro and in vivo 29 activation of mGluR5 in rats, we identify specific changes in intrinsic excitability and 30 synaptic plasticity in basolateral amygdala neurons that give rise to temporally distinct 31 and mutually exclusive effects on fear-related behaviors. The immediate impact of 32 mGluR5 activation is to produce anxiety manifested as indiscriminate fear of both tone 33 and context. Surprisingly, this state does not interfere with the proper encoding of tone- 34 shock associations that eventually lead to enhanced cue-specific fear. These results 35 provide a new framework for dissecting the functional impact of amygdalar mGluR- 36 plasticity on fear versus anxiety in health and disease.
    [Show full text]
  • G Protein‐Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology (2019) 176, S21–S141 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors Stephen PH Alexander1 , Arthur Christopoulos2 , Anthony P Davenport3 , Eamonn Kelly4, Alistair Mathie5 , John A Peters6 , Emma L Veale5 ,JaneFArmstrong7 , Elena Faccenda7 ,SimonDHarding7 ,AdamJPawson7 , Joanna L Sharman7 , Christopher Southan7 , Jamie A Davies7 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Victoria 3052, Australia 3Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK 4School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 5Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 6Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 7Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website.
    [Show full text]
  • Endogenous Activation of Group-I Metabotropic Glutamate Receptors Is Required for Differentiation and Survival of Cerebellar Purkinje Cells
    The Journal of Neuroscience, October 1, 2001, 21(19):7664–7673 Endogenous Activation of Group-I Metabotropic Glutamate Receptors Is Required for Differentiation and Survival of Cerebellar Purkinje Cells M. V. Catania,1 M. Bellomo,2 V. Di Giorgi-Gerevini,3 G. Seminara,1,4 R. Giuffrida,5 R. Romeo,6 A. De Blasi,7,8 and F. Nicoletti3,8 1Institute for Bioimaging and Pathophysiology of the Central Nervous System (IBFSNC), National Research Council (IBFSNC-CNR), 95123 Catania, Italy, 2Institute of Physiology, University of Messina, 98100 Messina, Italy, 3Department of Human Physiology and Pharmacology, University of Roma La Sapienza, Rome, Italy, Departments of 4Chemical Sciences and 5Physiological Sciences and 6Institute of Anatomy, University of Catania, 95100 Catania, Italy, 7Department of Molecular Pharmacology and Pathology, “Mario Negri Sud” Institute, 66030 S. Maria Imbaro (Chieti), and 8I. N. M. Neuromed, 86077 Pozzilli, Italy We have applied subtype-selective antagonists of metabo- early blockade of mGlu1 receptors induced in rats by local tropic glutamate (mGlu) receptors mGlu1 or mGlu5 [7-(hydroxy- injections of LY367385 (20 nmol/2 ␮l), local injections of mGlu1 imino) cyclopropa[b]chromen-1a-carboxylate ethyl ester (CPC- antisense oligonucleotides (12 nmol/2 ␮l), or systemic admin- COEt) or 2-methyl-6-(phenylethynyl)pyridine (MPEP)] to mixed istration of CPCCOEt (5 mg/kg, s.c.) from postnatal day (P) 3 to rat cerebellar cultures containing both Purkinje and granule P9 reduced the number and dramatically altered the morphol- cells. The action of these two drugs on neuronal survival was ogy of cerebellar Purkinje cells. In contrast, mGlu5 receptor cell specific.
    [Show full text]
  • ()-PHCCC, a Positive Allosteric Modulator of Mglur4
    Neuropharmacology 45 (2003) 895–906 www.elsevier.com/locate/neuropharm (Ϫ)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and neuroprotection M. Maj a,1, V. Bruno b,1, Z. Dragic a, R. Yamamoto a, G. Battaglia b, W. Inderbitzin a, N. Stoehr a, T. Stein a, F. Gasparini a, I. Vranesic a, R. Kuhn a, F. Nicoletti b,c, P.J. Flor a,∗ a Novartis Institutes for BioMedical Research, Neuroscience Disease Area, WKL-125.6.08, Basel CH-4002, Switzerland b Istituto Neurologico Mediterraneo, Neuromed, Pozzilli, Italy c Department of Human Physiology and Pharmacology, University of Rome, Rome, Italy Received 25 February 2003; received in revised form 27 May 2003; accepted 23 June 2003 Abstract Group-III metabotropic glutamate receptors (mGluR4, -6, -7, and -8) modulate neurotoxicity of excitatory amino acids and beta- amyloid-peptide (bAP), as well as epileptic convulsions, most likely via presynaptic inhibition of glutamatergic neurotransmission. Due to the lack of subtype-selective ligands for group-III receptors, we previously utilized knock-out mice to identify mGluR4 as + the primary receptor mediating neuroprotection of unselective group-III agonists such as L-AP4 or ( )-PPG, whereas mGluR7 is critical for anticonvulsive effects. In a recent effort to find group-III subtype-selective drugs we identified (+/Ϫ)-PHCCC as a positive allosteric modulator for mGluR4. This compound increases agonist potency and markedly enhances maximum efficacy and, at higher concentrations, directly activates mGluR4 with low efficacy. All the activity of (+/Ϫ)-PHCCC resides in the (Ϫ)-enantiomer, which is inactive at mGluR2, -3, -5a, -6, -7b and -8a, but shows partial antagonist activity at mGluR1b (30% maximum antagonist efficacy).
    [Show full text]
  • Identification and Analysis of Hepatitis C Virus NS3 Helicase Inhibitors Using Nucleic Acid Binding Assays Sourav Mukherjee1, Alicia M
    Published online 27 June 2012 Nucleic Acids Research, 2012, Vol. 40, No. 17 8607–8621 doi:10.1093/nar/gks623 Identification and analysis of hepatitis C virus NS3 helicase inhibitors using nucleic acid binding assays Sourav Mukherjee1, Alicia M. Hanson1, William R. Shadrick1, Jean Ndjomou1, Noreena L. Sweeney1, John J. Hernandez1, Diana Bartczak1, Kelin Li2, Kevin J. Frankowski2, Julie A. Heck3, Leggy A. Arnold1, Frank J. Schoenen2 and David N. Frick1,* 1Department of Chemistry and Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, WI 53211, 2University of Kansas Specialized Chemistry Center, University of Kansas, 2034 Becker Dr., Lawrence, KS 66047 and 3Department of Biochemistry and Molecular Biology, New York Medical College, Valhalla, NY 10595, USA Received March 26, 2012; Revised May 30, 2012; Accepted June 4, 2012 Downloaded from ABSTRACT INTRODUCTION Typical assays used to discover and analyze small All cells and viruses need helicases to read, replicate and molecules that inhibit the hepatitis C virus (HCV) repair their genomes. Cellular organisms encode NS3 helicase yield few hits and are often con- numerous specialized helicases that unwind DNA, RNA http://nar.oxfordjournals.org/ founded by compound interference. Oligonucleotide or displace nucleic acid binding proteins in reactions binding assays are examined here as an alternative. fuelled by ATP hydrolysis. Small molecules that inhibit After comparing fluorescence polarization (FP), helicases would therefore be valuable as molecular homogeneous time-resolved fluorescence (HTRFÕ; probes to understand the biological role of a particular Cisbio) and AlphaScreenÕ (Perkin Elmer) assays, helicase, or as antibiotic or antiviral drugs (1,2). For an FP-based assay was chosen to screen Sigma’s example, several compounds that inhibit a helicase Library of Pharmacologically Active Compounds encoded by herpes simplex virus (HSV) are potent drugs in animal models (3,4).
    [Show full text]